uniQure (NASDAQ:QURE) Share Price Passes Below 200-Day Moving Average of $6.06

uniQure (NASDAQ:QURE - Get Free Report)'s stock price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.06 and traded as low as $4.66. uniQure shares last traded at $4.71, with a volume of 440,845 shares.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on QURE. Royal Bank of Canada restated an "outperform" rating and issued a $28.00 price target on shares of uniQure in a research report on Tuesday, January 16th. HC Wainwright dropped their price objective on uniQure from $30.00 to $25.00 and set a "buy" rating on the stock in a research note on Friday, March 1st. The Goldman Sachs Group downgraded uniQure from a "buy" rating to a "neutral" rating and dropped their price objective for the stock from $63.00 to $8.00 in a research note on Thursday, February 29th. StockNews.com raised uniQure to a "sell" rating in a research note on Friday, March 1st. Finally, Mizuho dropped their price objective on uniQure from $10.00 to $7.00 and set a "neutral" rating on the stock in a research note on Monday, March 4th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, uniQure currently has a consensus rating of "Moderate Buy" and an average target price of $32.00.

uniQure Trading Down 0.8 %

The company has a market cap of $223.40 million, a P/E ratio of -0.72 and a beta of 0.95. The business has a fifty day moving average price of $5.39 and a 200-day moving average price of $6.06. The company has a quick ratio of 8.68, a current ratio of 8.85 and a debt-to-equity ratio of 0.49.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.54) by $0.01. uniQure had a negative return on equity of 99.31% and a negative net margin of 1,947.09%. The company had revenue of $6.69 million during the quarter, compared to analysts' expectations of $3.20 million. On average, analysts forecast that uniQure will post -4.49 earnings per share for the current year.

Insider Activity

In other news, COO Pierre Caloz sold 9,455 shares of uniQure stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $6.47, for a total value of $61,173.85. Following the completion of the sale, the chief operating officer now directly owns 85,643 shares in the company, valued at $554,110.21. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other uniQure news, CEO Matthew C. Kapusta sold 27,904 shares of the business's stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $6.35, for a total transaction of $177,190.40. Following the completion of the transaction, the chief executive officer now directly owns 440,839 shares in the company, valued at $2,799,327.65. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Pierre Caloz sold 9,455 shares of the business's stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $6.47, for a total transaction of $61,173.85. Following the transaction, the chief operating officer now owns 85,643 shares of the company's stock, valued at $554,110.21. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 53,265 shares of company stock worth $339,845. Corporate insiders own 4.05% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Citigroup Inc. increased its holdings in shares of uniQure by 667.9% during the third quarter. Citigroup Inc. now owns 766,521 shares of the biotechnology company's stock worth $5,143,000 after buying an additional 666,696 shares in the last quarter. Algert Global LLC increased its holdings in shares of uniQure by 237.6% during the third quarter. Algert Global LLC now owns 414,241 shares of the biotechnology company's stock worth $2,780,000 after buying an additional 291,541 shares in the last quarter. Jump Financial LLC acquired a new position in shares of uniQure during the third quarter worth $823,000. Swiss National Bank increased its holdings in shares of uniQure by 8.0% during the third quarter. Swiss National Bank now owns 99,400 shares of the biotechnology company's stock worth $667,000 after buying an additional 7,400 shares in the last quarter. Finally, Hudson Bay Capital Management LP increased its holdings in shares of uniQure by 66.0% during the third quarter. Hudson Bay Capital Management LP now owns 390,200 shares of the biotechnology company's stock worth $2,618,000 after buying an additional 155,100 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.